LGVN קפיטליזציה חשבונאית Longeveron

Longeveron Inc. (LGVN) business specifics rely on the highly complex transportation of biomaterials in liquid nitrogen to preserve their properties. This price chart on the GURU.Markets platform illustrates the asset's dynamics, where the current figure is 0.01. Professional management guarantees transparency of R&D data, while the primary growth driver is the clinical trials of the Lomecel-B drug against Alzheimer's disease, the risks of which investors have already priced in.

Book value reflects the value of net assets minus all liabilities, allowing an investor to assess the business's actual internal reserves regardless of market volatility. For Longeveron Inc. (LGVN), the company's current book capital demonstrates the burn rate of funds spent on costly stem cell research, which, in the absence of revenue, signals a gradual decline in financial stability.